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specific pre-existing antibodies, and complement alternative
pathway activation can be initiated directly by allergen
polysaccharide structures. In addition, proteases directly
activated by mite or mast cell tryptase or released by mucosal
epithelial cells can generate complement split-product proteins
during allergic reaction.3 Bowser et al8 first demonstrated that
complement split products correlate with asthma severity and
that changes in C3a and C5a levels reflect cutaneous allergic
responses from dust mites after immunotherapy.
Downregulation of the effector T-cell response through
development of a T-cell lineage with suppressive properties
might be a novel role for complement in the contraction of
an immune response.4 The complement regulatory protein
CD46 can induce the development of a distinct immuno-
modulatory T-cell population similar to adaptive IL-10–
producing TR1 cells.
5-7 Further understanding how CD46
activates IL-10–producing TR1 cells during D pteronyssinus
SIT and the dose of mite allergens might be important. The
total dust mite SIT dosage has been reported to be
associated with changes in C5a and C3a levels, and this
might be due to activation of the complement activation by
D pteronyssinus proteases, endotoxin, or both in multiple
allergen extracts.8
CD3/CD46-activated TR1-like cells permit dendritic cell
activation through their simultaneous secretion of GM-CSF and
soluble CD40, which could be desirable in mucosal tolerance.9
In the airway the cytokine profile of complement-activated
Treg cells might ensure unresponsiveness to allergen-mediated
complement activation by suppressing an unwanted T-cell
response through IL-10 while maintaining reactivity to invading
pathogens.6
In summary, we have provided evidence that D pteronyssinus
SIT can enhance the suppressive function of IL-10/IFN-g in
CD3/CD46-activated TR1-like cells from asthmatic patients,
and this might explain the dysfunctional ability of Treg cells to
suppress mite-induced airway epithelial cell inflammation. On
the basis of these results, it might be possible to design therapeutic
strategies to manipulate the complement-activated Treg cells to
achieve allergen tolerance and suppress airway inflammation in
patients with allergic asthma.
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Gain-of-function mutations in signal trans-
ducer and activator of transcription 1 (STAT1):
Chronic mucocutaneous candidiasis accompa-
nied by enamel defects and delayed dental
shedding
To the Editor:
Heterozygous gain-of-function mutations in signal transducer
and activator of transcription 1 (STAT1) have recently been
identified as a cause of chronic mucocutaneous candidiasis
(CMC). Uzel et al1 described ‘‘STAT1 gain-of-function mutations
in patients with FOXP3 wild-type immune dysregulation-
polyendocrinopathy-enteropathy-X-linked syndrome.’’ They
briefly mentioned the presence of poor enamel in 1 patient and
structural and functional gastrointestinal defects in another
patient. Herewe present a patient with CMC associatedwith dental
anomalies, diaphragmatic hernia, and esophageal dysmotility in
whom the phenotype led to a broad differential diagnosis ranging
from severe combined immunodeficiency inspired by the neonatal
onset of infections to humoral immune deficiency, immune
dysregulation–polyendocrinopathy–enteropathy–X-linked syn-
drome, nuclear factor kB essential modulator (NEMO) deficiency,
Shwachman-Diamond syndrome, autosomal dominant hyper-IgE
syndrome, and, finally, CMC caused by gain-of-function mutation
in STAT1.We stress the early onset of respiratory tract infections, as
well as the dental and gastrointestinal defects, in this patient.
The patient was born at term small for gestational age (22 SD)
as the third son of unrelated parents. He presented with recurrent
lower respiratory tract infections from birth, intractable diarrhea,
failure to thrive, seborrheic dermatitis, and CMC. Small-bowel
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=FIG 2. The mutant T385M STAT1 allele is a gain-of-phosphorylation and gain-of-function mutation.
A, Direct sequence analysis of exon 14 of STAT1 (forward sequence) in a control subject and the patient
with a c.1153C>T resulting in p.T385M. B, Intracellular staining of phosphorylated tyrosine 701 STAT1
(STAT1p) in lymphocytes after stimulation with IFN-g (2000 IU/mL, left panel) or IFN-a (105 IU/mL, right
panel) for 15 minutes. STAT1 and STATp are shown in a control subject (red) and in the T385M patient
(blue). Unstimulated conditions are represented as dashed lines. Results shown are representative of 2
independent experiments. MFI, Mean fluorescence intensity. C, Evaluation of STAT1, STAT1 phosphoryla-
tion, and STAT1p GAS DNA-binding capacity. Fibroblasts derived from wild-type (WT)/WT control subjects
(C1 and C2), p.T385M/WT (patient P1), and p.K388E/WT (patient P2) were stimulated with 100 U/mL IFN-a (a)
or 100 U/mL IFN-g (U) or left unstimulated (2) for 60 minutes. a, Western blotting was carried out for
detection of STAT1 and STAT1p levels in nuclear extracts (5 mg per sample). Heterogeneous nuclear
ribonucleoprotein I (hnRNP I) was used as a loading control reference. b, STAT1 GAS DNA-binding capacity
was evaluated by using EMSA. Onemicrogram of nuclear extract was preincubated with 20,000 cpm of GAS
probe at room temperature before nondenaturing PAGE separating free from STAT-bound probe.
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yet diarrhea was unresponsive to a gluten-free diet. Primary
dentition showed enamel defects. Recurrent lower respiratory
tract infections with Haemophilus influenzae and Streptococcus
pneumoniae led to the development of bronchiectasis. Partial
IgG2 deficiency (0.34 g/L; normal range, 0.72-3.4 g/L) was found
at 3 years of age. Anti-tetanus antibody levels were protective
(1.2 mg/L; protective level, >1 mg/L), suggesting an intact
anti-protein antibody response. Intravenous immunoglobulin
(IVIG) substitution was initiated. Diaphragmatic hernia, gastro-
esophageal reflux disease, and disturbed esophageal motility
were demonstrated and led to a Nissen fundoplication.
At 13 years of age, the patient presented at the immunology
clinic with severe growth retardation (Fig 1, A), pubertal delay,
bronchiectasis, atonic esophagus with multiple diverticula
(Fig 1,B andC), atrophic duodenalmucosa (Fig 1,D) correspond-
ing to villous blunting or atrophy, joint hyperlaxity, osteopenia
with recurrent fractures, delayed dental development with
retention of primary teeth necessitating dental extractions
(Fig 1, E and F), severe erosive tooth wear suggestive of enamel
hypoplasia (Fig 1, E and F), seborrheic dermatitis, aphthousFIG 1. Clinical characteristics. A, Growth charts showin
growth hormone therapy and puberty induction with tu
feeding and growth hormone therapy, respectively
esophagus (arrow) with air containing paraesophagea
showing multiple saccular bronchiectases and bronch
as seen on endoscopy. E and F, Severe erosive tooth wstomatitis, and CMC (see Table E1 in this article’s Online
Repository at www.jacionline.org). The autoimmune regulator
(AIRE) and caspase recruitment domain family, member 9
(CARD9), genes were sequenced, but no mutations were found.
After withdrawal of IVIG, antibody response to unconjugated
pneumococcal vaccine was tested and showed protective titers
for 9 of 14 serotypes tested (see Table E2 in this article’s Online
Repository at www.jacionline.org).2 Increased IgG levels (21 g/L;
normal range, 5.76-12.65 g/L) and persistent partial IgG2
deficiency were noted (0.80 g/L; normal range, 1.06-6.10 g/L).
An extended autoantibody screening panel was performed,
including thyroid-related, adrenal gland–related, and anti–
IFN-a and anti–IFN-v antibodies. Only anti–salivary gland
antibodies were demonstrated (for the entire panel, see
the Methods section in this article’s Online Repository at
www.jacionline.org). Immunophenotyping showed a low
percentage of switched memory B cells (1.3%; normal range,
5% to 10%; see Table E3 in this article’s Online Repository at
www.jacionline.org). Because withdrawal of IVIG was associ-
ated with an increased incidence of pneumonia, treatment was
optimized by restarting IVIG and initiating azithromycin (bothg severe growth retardation that only picks up after
be feeding overnight. Arrows indicate onset of tube
. B, Computed tomography showing an atonic
l diverticula. C, Computed tomography of the chest
ial wall thickening. D, Atrophy in the duodenum,
ear, caries, and retained primary teeth.
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and fluconazole prophylaxis, as well as overnight tube feeding.
Growth hormone therapy and puberty induction led to a
correction of the growth deficit (Fig 1, A). Finally, at the age of
18 years, hypothyroidism was diagnosed almost simultaneously
with the initial reports on STAT1 coiled-coil domain gain-of-
function mutations.3,4 A mutation in the DNA-binding domain
of STAT1was detected (c.1154C>T, p.T385M; Fig 2, A; for infor-
mation on the analysis, see the Results section in this article’s
Online Repository at www.jacionline.org). The mutation was
not found in the parents or the 2 male siblings of the index patient.
As described previously, T385M is a gain-of-function muta-
tion.1,5-7 Likewise, we showed increased STAT1 phosphorylation
in response to IFN-a and IFN-g in the patient compared with
control values (Fig 2, B). Also, the electrophoretic mobility shift
assay (EMSA) showed increased gamma-activated sequence
(GAS) binding activity on stimulation with IFN-g (Fig 2, C).
The mechanism that leads to gain of function in the T385M
mutation is not entirely clear. Takezaki et al5 suggested an
impaired dephosphorylation of STAT1. However, it is also
possible that there is impaired dissociation from the DNA or a
problem with the reciprocal association of the DNA-binding
domain with the coiled-coil domain. After diagnosis, extended
immunophenotyping of PBMCs was performed and showed
absence of TH17 cells, as described by Liu et al.
4
The dental anomalies in the patient were impressive. Both
primary and permanent teeth showed rapid loss of tooth
substance, with severe caries and erosive tooth wear
reminiscent of the dental anomalies encountered in patients
with Shwachman-Diamond syndrome or Ora1/Stromal interac-
tion molecule 1 deficiency. Moreover, deciduous teeth had to be
extracted because of delayed shedding. The latter feature
resembles autosomal dominant hyper-IgE syndrome.
Several hypotheses to explain the dental anomalies were put
forward. First, antibiotic and antimycotic therapy and acidic
hypercaloric nutrition were blamed. Second, malabsorption of
calcium and vitamin D was investigated. Third, in the context of
recurrent aphthous stomatitis, a sicca syndrome was suspected.
Although salivary flow was low, treatment with oral saliva
analogues did not improve the dental condition. There were no
biochemical or clinical signs of hypothyroidism until age 18 years
in our patient, excluding this as a cause for the delayed shedding
of deciduous teeth. Although a role for STAT1 signaling has been
demonstrated in amelogenesis and dentinogenesis in rats, further
research is needed to investigate the potential causal relationship
between STAT1 gain-of-function mutation and abnormal dental
development.8,9
Aside from the persistent villous blunting, diaphragmatic
hernia and esophageal dysmotility are remarkable gastrointestinal
features. On computed tomographic (CT) scanning, as well as
endoscopy, the esophagus appeared wide open and atonic, with
multiple diverticula present. Thus defects in the development of
the upper gastrointestinal tract seem to be a noteworthy feature of
this syndrome, as hypothesized by Uzel et al.1 Whether the
gastrointestinal manifestations are all secondary to CMC or a
primary manifestation of disturbed STAT1 signaling is yet to be
determined.1,6
In conclusion, we report extensive dental anomalies, as well as
diaphragmatic hernia and esophageal dysmotility, in a
patient with early onset of lower respiratory tract infections inthe context of a gain-of-function mutation in the DNA-binding
domain of STAT1. These features add to the complexity of the
phenotype observed in patients with a gain-of-function mutation
in STAT1.
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FIG 1. Comparison of allergen-specific IgG levels (ISAC standardized unit
[ISU]) measured in different plasma dilutions of 4 mothers with allergen-
specific IgG levels in their breast milk samples.
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Transmission of allergen-specific IgG and IgE
from maternal blood into breast milk visual-
ized with microarray technology
To the Editor:
Data from experimental animal models have previously shown
that allergen-specific IgG antibodies are transmitted from the
mother to the offspring via breast milk1,2 and have provided evi-
dence that the transmitted allergen-specific IgG antibodies protect
specifically against allergic sensitization.2 In some studies, it has
been demonstrated for humans that breast-feeding has a prophy-
lactic effect against atopic disease but there are also reports
arguing against this and the underlying mechanisms are not
known.3 There is evidence that IgG antibodies against bacterial
antigens (ie, pneumococcal antigens) are transferred from the
blood of mothers into their breast milk.4 Furthermore, it was
possible to detect IgA and IgG against different food antigens
in human serum, saliva, colostrums, and milk samples.5 Another
study found that total IgE levels in breast milk and blood were
associated but allergen-specific IgE was not analyzed.6
With the FP7-funded European Union research program
Mechanisms of the Development of ALLergy (MeDALL;
http://medall-fp7.eu/), we have recently developed a microarray
containing a large number of purified natural and recombinant
respiratory, food, and insect allergens that allows highly sensi-
tive measurement of allergen-specific IgE and IgG levels with
minute amounts of blood.7 A major advantage of the microarray
technology is that it allows one to measure antibody reactivities 2014 The Authors. Published by Elsevier Inc. on behalf of the American Academy of
Allergy, Asthma & Immunology. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/3.0/).toward a large panel of different allergens. Here, we investi-
gated whether the MeDALL chip is suitable for (1) the measure-
ment of allergen-specific IgG and IgE levels in human breast
milk samples, (2) whether there is a transmission of allergen-
specific antibodies from blood into breast milk, and (3) whether
the reactivity profile of allergens recognized by antibodies in
blood and milk is similar. For this purpose, we analyzed plasma
and breast milk samples from sensitized (n 5 23) and nonal-
lergic mothers (n 5 6) from the ALADDIN birth cohort.8
None of the mothers was on allergen-specific immunotherapy.
Maternal blood samples were collected in the period around
delivery (21 to 12 months), and the breast milk samples
were obtained 2 months after delivery. The study was approved
by the local Research Ethical Committee, and written informed
consent was obtained from all families.
The breast milk samples were centrifuged for 10 minutes at
2500g before use to remove the lipids. For comparison of IgG
titers in plasma and breast milk, the plasma samples were diluted
1:50, 1:100, 1:200, and 1:400 before analysis. Microarrays were
incubated with 30 mL of the plasma dilutions or undiluted breast
milk samples and allergen-specific IgG and IgE antibodies were
detected with fluorophore-conjugated anti-IgG and anti-IgE
antibodies, respectively.7 The fluorescence intensities were
measured with a biochip scanner. Results were expressed in
ISAC standardized units (Thermofisher, Uppsala, Sweden).
Correlation coefficients were calculated with SPSS.
Detailed analysis of allergen-specific IgG and IgE levels in
plasma and breast milk samples indicated that allergen-specific
IgG antibodies are transmitted from the blood into breast milk in a
highly specific manner and that breast milk IgG mirrored the
profile of IgG reactivity in the blood (see Fig E1 in this article’s
Online Repository at www.jacionline.org). A comparison of
allergen-specific IgG levels measured in 4 plasma dilutions with
that of undiluted breast milk samples (Fig 1) indicated that
allergen-specific IgG levels in breast milk were approximately
200- to 400-fold lower than in plasma. Allergen-specific IgG re-
activities in plasma and breast milk were significantly correlated;
for the 1:200 dilution, Spearman correlation coefficient was 0.608
(P < .001) and for the 1:400 dilution, Spearman correlation coef-
ficient was 0.604 (P < .001) (Fig 2). Detailed results are displayed
METHODS
Measurement of salivary flow rate
Salivary flow rate was measured through standardized collection of
nonstimulated (resting) and stimulated (paraffin-chewing) saliva over a time
span of 5 minutes.
Autoantibody analysis
The autoantibody panel analyzed consisted of anti–nuclear antigen,
anti–neutrophil cytoplasmic, anti-thyroglobulin, anti–thyroid peroxidase,
anti–thyrotropin receptor, anti–parietal cell, anti–intrinsic factor,
anti–smooth muscle, anti-mitochondrial, anti-pancreatic, anti-insulin,
anti-GAD65kDA, anti–liver kidney microsome, anti–proteinase 3,
anti-myeloperoxidase, and anti–IFN-a and anti–IFN-v antibodies. The
latter analysis was performed by Anette S. Boe Wolff and Husebye
Eystein, Bergen, Norway, because of the diagnostic value in patients with
autoimmune polyendocrine syndrome type 1.E1
Genetic analysis
Genomic DNA was extracted from EDTA blood by using the QIAamp
DNA Blood Mini Kit (Qiagen, Hilden, Germany). The UM13F/R-tagged
primers (Life Technologies, Ghent, Belgium) used for genotyping STAT1
hotspots (gene ID 6772, ENSG00000115415) were designed with Oligo7
software (OLIGO Primer Analysis Software Version 7, assembled in 2009
by Wojciech Rychlik, Molecular Biology Insights, Cascade, Colo; http://
www.oligo.net/) and were as follows, respectively: AGTACAATAAAG
TAAACATTCTGC (F1) and CTAAATCTGATTCTCCCACTT (R1); AGT
CACACCCTGAAGAAAACGATG (F2) and CTGCAAAATTTTTCTTCC
CAA (R2); AGTCTAAAGTCTTTGGAAGTTGCT (F3) and CTGGCCT
GGGTTATCAAGGAA (R3); AGTTCTTCTTTATATATTTACTGG (F4)
and GGTGGCTATAATTTTTCCTCT (R4); AGTTGAGAATGAAATGA
TATTTGC (F5) and GTGTTTATGTGGTTAGCCAGT (R5); AGTCTTCTG
GACTGTTTCTCATAG (F6) and ATCATCTGAATTAACGGTAAA (R6);
AGTCCTCAACCTTAATGGAAATGC (F7) and CTCAAAAGCACCCTA
TATAAC (R7); AGTAAACGTTAATAGGGAATTGGC (F8) and CCTAGG
GAGGCAAACTTCCAC (R8); and AGTCTCTTATAATTTTGTTAAAGC
(F9) and CCTACCAGGTGCCGAAATTCA (R9).
PCR samples were prepared by using AccuPrime SuperMix II (Life
Technologies, Belgium) and run on a Veriti Thermal Cycler (Applied
Biosystems, Foster City, Calif). Purified PCR products (PCR purification
kit, Qiagen) were sequenced by BaseClear (Leiden, The Netherlands) and
analyzed with Chromas 2.33 Software.
Analysis of phosphorylated STAT1 by using flow
cytometry
Peripheral blood was left unstimulated or stimulated with IFN-g
(2000 IU/mL) or IFN-a (10*5 IU/mL) for 15 minutes. Cells were lysed
(Lyse/Fix Buffer; BD Phosflow; BD Biosciences, San Jose, Calif) for
10 minutes at 378C and washed with 1 mL of Stain Buffer (BD PharMingen,
San Jose, Calif). Thereafter, the cells were permeabilized (Perm Buffer III
[BD Phosflow]) for 30 minutes on ice. Cells were washed, resuspended in
100 mL of stain buffer, and stained with phycoerythrin-labeled antibody
specific for phosphorylated STAT1 (pY701; BD Biosciences). Phosphory-
lated STAT1 was evaluated in the lymphocyte gate. Analysis was performed
on a FACSCanto II instrument (BD Biosciences).
Western blot analysis
Nuclear extracts of patient- or control subject–derived fibroblast
(obtained from skin biopsy) cultures (unstimulated or stimulated with
IFN-a [100 U/mL] or IFN-g [100 U/mL] for 1 hour) were prepared, as
described previously.E2 Nuclear protein lysates (5 mg per sample) were
subjected to SDS-PAGE separation on 4-12% Bis-Tris Plus gels (Life Tech-
nologies, Carlsbad, Calif), and proteins were transferred to a polyvinylidene
difluoride membrane (GE Healthcare, Buckinghamshire, United Kingdom)
and immunoblotted with primary antibodies (STAT1 p84/p91 [M-22,
sc-592; Santa Cruz Biotechnology, Dallas, Tex], phospho-STAT1 [Tyr701,
sc-7988, Santa Cruz Biotechnology], and loading control heterogeneous
nuclear ribonucleoprotein I [3H7, sc-73391, Santa Cruz Biotechnology])
and detected with horseradish peroxidase–conjugated secondary antibody
(sc-2317 and sc-2005, Santa Cruz Biotechnology). All Western blot images
were captured and quantified with a ChemiDoc MP imager and Image Lab
software (Bio-Rad Laboratories, Hercules, Calif) after adding Pierce ECL
Western blotting substrate (Thermo Scientific, Waltham, Mass). Relative
phosphorylated STAT1 expression is normalized to the respective value for
heterogeneous nuclear ribonucleoprotein I expression, and the results are
described as fold increases relative to the baseline level in the unstimulated
condition of the sample.
EMSA
EMSAwas performed, as described previously.E2 Probe (20,000 cpm) was
added to 1 mg of nuclear extract in 50 ng/mL dI-dC, 1 mmol/L dithiothreitol,
and 0.05% Triton. EMSA results with nonstimulated extracts or extracts
stimulated with IFN-a or IFN-gwere compared. The GAS probe (59-TCGAA
CATTTCCCGTAAATCATG-39, Chapgier et alE3) was labeled by a fill-in
reaction with the Klenow fragment. EMSA results with nonstimulated
extracts (dimethyl sulfoxide vehicle treated) or extracts stimulated with
IFN-a (100 U/mL) or IFN-g (100 U/mL) were compared in 2 control subjects
(C1 and C2), the T385M patient (P1), and a patient with CMC with a K388E
mutation in the DNA-binding domain (P2). Intensities of GAS-binding
activity were determined by using ImageJ software.E4
Stimulation of PBMCs and measurement of
cytokines
PBMCs were prepared from heparinized peripheral blood by means of
centrifugation through Ficoll (Lymphoprep, Axis-shield, Oslo, Norway).
PBMCs were seeded at 23 106 cells/mL in a 96-well culture plate and stim-
ulated with heat-inactivated Candida albicans (2.64 3 103 colony-forming
units [CFU]/mL), Staphylococcus aureus (108 CFU/mL; InvivoGen, San
Diego, Calif), or PHA (0.18 mg/mL). IFN-g levels were measured in the su-
pernatant after 48 hours of incubation at 378C (5% CO2) and IL-17A levels
were measured after 120 hours of incubation at 378C (5% CO2) by means of
ELISA (commercial kits by BD Biosciences and BioLegend [San Diego,
Calif], respectively). For the production of heat-inactivated C albicans, refer-
ence strain ATCC 90028was used. This strain was cultured on Sabouraud agar
slants at 378C. Yeast colonies were resuspended in RPMI agar and checked
microscopically for the absence of hyphae. This yeast stock suspension was
adjusted to a concentration of 0.4 3 107 CFU/mL. C albicans was subse-
quently heat killed by exposure to a 608Cwater bath for 1.5 hours. The sterility
of this suspension was checked by subculturing 50 mL of the yeast suspension
on blood agar at 378C.
Immune response to Pneumovax
Antibodies to pneumococcal polysaccharides were measured by using a
mulitplex bead assay.E5
Extended peripheral blood immunophenotying
panel
PBMC immunophenotyping was performed, as described previously.E6 In
brief, PBMCs were isolated from heparinized blood of the patient and 10
age-matched control subjects (mean age, 22.7 years [SD, 4.62 years]) by using
lymphocyte separation medium (MP Biomedicals, Santa Ana, Calif) and
frozen in 10% dimethyl sulfoxide (Sigma, St Louis, Mo). Thawed cells
were stained with eBioscience (San Diego, Calif) antibodies against CD3
(SK7), CD4 (RPA-T4), and IL-17 (eBio64DEC17). For cytokine staining,
T cells were stimulated ex vivo for 5 hours in 50 ng/mL phorbol
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12-myristate 13-acetate (Sigma) and 500 ng/mL ionomycin (Sigma) in the
presence of GolgiStop (BD Biosciences) before staining. Before intracellular
staining, cells were first surface stained as described, fixed, and permeabilized
with Cytofix/Cytoperm (BD) for IL-17 stainings. Data were acquired on BD
FACSCanto II and analyzed with FlowJo software (Tree Star, Ashland, Ore).
RESULTS
Salivary flow rate
The nonstimulated salivary flow rate in the index patient
was less than 0.2 mL/5 minutes; the stimulated flow rate was
3.1 mL/5 minutes.
T385M is a gain-of-function mutation
On stimulation with IFN-a and IFN-g, higher levels of STAT1
phosphorylation were observed bymeans of flow cytometry in the
patient compared with those seen in a control subject (Fig 2, B).
Next, we studied STAT1-binding activity to a GAS oligonucleo-
tide probe by using EMSA. First, we studied the STAT1 phophor-
ylation in skin-derived fibroblasts using Western blotting. We
demonstrated an increased expression of total STAT1 in both
the T385M patient (P1) and a second patient with CMC caused
by a novel mutation in the DNA-binding domain (K388E; P2),
although less pronounced than that in P2, compared with that
seen in 2 healthy control subjects. Expression of phosphorylated
STAT1 was increased in the nuclear extracts of both the T385M
and K388E patients, although again less pronounced in the latter,
after stimulation for 1 hour with IFN-g. The phosphorylation of
STAT1 in P1 and P2 was 7 and 2.7 times more intense than in
C2 (Fig 2, C). On stimulation with IFN-g, an increase in GAS-
binding activity was detected in the T385M patient (P1; Fig 2,
C), as well as in the K388E patient (P2). The intensity of
STAT1-binding activity to a GAS probe was quantified to be
16.8 and 2.4 times upregulated in P1 and P2, respectively,
compared with the intensity in C2, which was set to 1 in ImageJ
software.
PBMCs of the patient do not induce IL-17
PBMCs of the patient do not induce IL-17 after stimulation
with heat-inactivated C albicans, S aureus, or PHA. IL-17 in the
supernatant was undetectable after stimulation with the
above-mentioned stimuli (Fig E1, A). IFN-g production after
stimulation with PHA, heat-inactivated C albicans, and S aureus
in the patient and a control subject are also shown (Fig E1, B).
Extended immunophenotyping at age 20 years
Using extended immunophenotyping, we showed that the
patient has no detectable TH17 cells.
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FIG E1. A, IL-17 production in PBMCs of the T385M patient and a healthy control subject after stimulation
with PHA, heat-inactivated C albicans, or heat-inactivated S aureus. Results shown are derived from one
representative experiment of 4 independent experiments. B, IFN-g production in PBMCs of the T385M
patient and a healthy control subject after stimulation with PHA, heat-inactivated C albicans, or
heat-inactivated S aureus. Results shown are derived from one representative experiment of 4 independent
experiments. HKCA, Heat-killed C albicans; HKSA, heat-killed S aureus.
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TABLE E1. Clinical characteristics
Present age 20 y
Ethnicity White
Initial presentation At birth
CMC Oral, esophageal, skin
Teeth Retained primary dentition, severe caries and
erosive tooth wear
Skin Severe seborrheic dermatitis
Pulmonary infections From birth
Haemophilus influenzae, Streptococcus
pneumoniae, Pseudomonas aeruginosa
Aspergillus fumigatus
Bronchiectasis at age 3 y, chronic obstructive
pulmonary disease
Other infections Molluscum contagiosum, Pseudomonas
folliculitis, herpes zoster (23)
Cardiovascular 2
Central nervous system 2
Endocrine At birth: small for gestational age
Growth retardation
Delayed puberty
Hypothyroidism (antibodies 2) at age 18 y
Gastrointestinal Oral aphthous ulcers, recurrent ulcerative
gastritis, esophagitis
Duodenal atrophic mucosa, villous blunting
Diaphragmatic hernia
Bone Osteopenia, multiple fractures
Other Cystic fibrosis and primary ciliary dyskinesia
were excluded.
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TABLE E2. Specific anti-pneumococcal antibody concentrations (in milligrams per miter) in the patient 3 weeks after vaccination with
unconjugated pneumococcal vaccine
PS1 PS3 PS4 PS8 PS9N PS12F PS14 PS19F PS23F PS6B PS7F PS18C PS19A PS9V
Patient 0.28 0.37 2.33 0.20 1.31 0.38 6.37 2.71 5.44 4.11 1.35 2.52 0.91 2.81
Cutoff 0.53 0.64 0.49 1.02 0.63 0.46 0.57 0.74 0.24 0.80 1.45 0.34 0.96 0.69
The postvaccination serotype-specific fifth percentile (Cutoff) values obtained in 75 healthy subjects are provided as well. PS, Pneumococcal serotype.
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TABLE E3. Immunologic characteristics
Age 1 y Age 3 y Age 13 y Age 20 y*
Lymphocyte subsets
CD191 B cells 622/mL (82-476/mL)
Naive CD191CD272 cells 94% of CD191 (60-80)
IgM memory CD271IgM1 cells 1.3% of CD191 (1-5)
Switched memory CD271IgM2 cells 1% of CD191 (>5)
CD31CD41T cells 886/mL (455-1885 mL)
CD31CD81 T cells 459/mL (219-1124/mL)
Naive CD41 cells 75% of CD3 (30% to 65%)
TH17 cells TH17 cells 0% (0.03-0.67)
Lymphocyte proliferation
PHA Normal Normal
Concanavalin A Normal Normal
Tetanus Normal Normal
Candida Normal Normal
Immunoglobulin levels (g/L)
IgG 16.7 (4.8-11.3) 21.4 (5.8-12.7) 22.8 (7.51-15.60)
IgG2 0.34 (0.72-3.40) 0.80 (1.06-6.10) 1.8 (1.5-6.4)
IgA 0.78 (0.35-1.9) 1 (0.81-2.32) 0.28 (0.82-4.53)
IgM 1.11 (0.34-1.34) 1.2 (0.30-1.59) 0.72 (0.43-3.04)
Normal values are shown in parentheses.
*During IVIG treatment.
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